<DOC>
	<DOC>NCT01632852</DOC>
	<brief_summary>This is a first in human, prospective, multicenter, nonrandomized, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of repeat doses of CSL362.</brief_summary>
	<brief_title>A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male or female aged 18 years or older. Previous diagnosis of CD123+ acute myeloid leukemia (AML), de novo or secondary. Completed and recovered from all planned induction and consolidation therapy according to the institution's standard of care, and achieved a complete remission (CR)/CR with incomplete platelet recovery (CRp); either first or second CR. Has factors conferring high risk of relapse. No plans for additional postremission chemotherapy. Not currently a candidate for allogeneic hematopoietic stem cell transplant (HSCT). Diagnosis of acute promyelocytic leukemia (APL). Known leukemic involvement of the central nervous system. Life expectancy 4 months or less as estimated by the investigator. Concurrent treatment or planned treatment with other anticancer therapy (chemotherapy, immunotherapy, radiotherapy, targeted therapy, gene therapy).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>